STOCK TITAN

Solid Biosciences (SLDB) DEF 14A Filings

SLDB NASDAQ

Here are the DEF 14A proxy statements from Solid Biosciences Inc. (SLDB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.

Rhea-AI Summary

Solid Biosciences Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 10, 2026. The company seeks to elect three Class II directors to terms ending in 2029 and ratify the advisory appointment of co‑founder Ilan Ganot as a Class I director through 2028.

Stockholders are also asked to ratify PricewaterhouseCoopers LLP as auditor for 2026, approve an amendment doubling authorized common stock from 240,000,000 to 480,000,000, and cast an advisory “say‑on‑pay” vote on executive compensation. The record date is April 16, 2026, with 98,413,277 common shares entitled to one vote each.